February 5, 2021

Immune Cells Suggest Men and Women with ALS May Benefit from Different Treatment

Effective treatments for ALS have eluded scientists for decades. A new examination of the immune system led by Dr. Benjamin Murdock shows the appeal of personalized medicine for future care.

from the M Health Lab Blog by Matt Trevor

Michigan Medicine Lab Blog Logo

A new study finds the immune systems for male and female patients with ALS, or amyotrophic lateral sclerosis, react differently to the disease.

Researchers say it’s the first step toward finding specific treatments for subsets of patients that could be more effective than the one-size-fits-all options currently available or in the pipeline.

“We know that the immune system is clearly linked to ALS onset and progression,” says Eva L. Feldman, M.D., Ph.D., the Russell N. DeJong Professor of Neurology and director of the ALS Center of Excellence at Michigan Medicine. “This is important as there are many existing and FDA-approved, immune-based drugs that could be repurposed to treat ALS. But we need to figure out which groups of patients - like men or women, old or young - could benefit from each drug.”

portrait of NeuroNetwork for Emerging Therapies faculty Dr. Benjamin Murdock

Benjamin Murdock, PhD

Robert A. Epstein and Joan M. Chernoff-Epstein Emerging Scholar
Research Assistant Professor of Neurology
Graduate Student Advisory Committee, Department of Immunology
Department of Neurology
5017 BSRB
Ann Arbor MI 48109-2200
Immune System in ALS
portrait of Dr. Eva Feldman

Eva Feldman, MD, PhD

James W. Albers Distinguished University Professor of Neurology
Russell N. DeJong Professor of Neurology
Director, NeuroNetwork for Emerging Therapies
Director, ALS Center of Excellence